Loading
FORT MYERS — NeoGenomics Inc., a leading provider of cancer-focused genetic testing services, has been awarded a group purchasing agreement for clinical reference laboratory testing services with Premier. Effective, Oct. 1, the new agreement allows Premier members to take advantage of special pricing and terms pre-negotiated by Premier for clinical reference laboratory services.
“The agreement underscores NeoGenomics’ unique position as a national, oncology-focused laboratory,” says NeoGenomics Chairman and CEO Douglas VanOort in a statement. “We look forward to providing a comprehensive suite of cancer tests to Premier members across the country.”
Based in Fort Myers, NeoGenomics provides expert bone marrow and surgical pathology consults, cancer cytogenetics with industry-leading turnaround times, hematologic and solid tumor FISH testing with the largest menu of technical-only services available, 10-color flow cytometry, histology supported by an extensive IHC antibody library, and >150 molecular oncology tests comprising the most comprehensive combination of multi-method tumor profiles and targeted biomarker tests in the industry.
Premier is a leading health care improvement company aligned with approximately 4,000 U.S. hospitals and 165,000 other providers.
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
